VALIDATED EXECUTIVE ENGAGEMENTS Number of executives repeatedly engaged by snail & email outreach* 
POOL + OUTREACH
| |||||||||||
The World of Immune Checkpoint Inhibitors is Changing Fast!It's Time to Identify Upcoming Revenue Pockets & Growth Areas. |
COVID-19 IMPACT SURVEYMonitor Market Dynamics!Early March 2020, we reached out to senior enterprise executives who are driving strategy, business development, marketing, sales, product management, technology and operations at competitive firms worldwide. Our ongoing survey is focused on how this will this affect their business ecosystems. We invite you to participate in our survey and add to collective perspectives. Market movements are tracked for 2020, 2021 and broadly for the period of 2022 through 2025. Critical changes are monitored dynamically for the rest of this year. Updated analytics will reflect new and evolving market realities. Our first update scheduled for May 2020 and another in the Fall. Clients receive complimentary updates during 2020. If your company is a recent client for this project, we may have already reached out to your colleagues to participate in our program. If you're an active player in the space but hasn't yet subscribed to our project, we invite you to participate and share your perspectives. Please sign-up here. Amid the COVID-19 crisis, the global market for Immune Checkpoint Inhibitors estimated at US$14.6 Billion in the year 2020, is projected to reach a revised size of US$50.7 Billion by 2027, growing at a CAGR of 19.4% over the analysis period 2020-2027.CLTA-4 Inhibitors, one of the segments analyzed in the report, is projected to grow at a 19.7% CAGR to reach US$10.8 Billion by the end of the analysis period.After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the PD-1 segment is readjusted to a revised 18.5% CAGR for the next 7-year period. This segment currently accounts for a 64.4% share of the global Immune Checkpoint Inhibitors market. The Immune Checkpoint Inhibitors market in the U.S. is estimated at US$4.4 Billion in the year 2020. The country currently accounts for a 30.4% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$7.4 Billion in the year 2027 trailing a CAGR of 16.2% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 15.6% and 17.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.8% CAGR while Rest of European market (as defined in the study) will reach US$7.4 Billion by the year 2027. In the global PD-L1 Inhibitors segment, USA, Canada, Japan, China and Europe will drive the 22.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.7 Billion in the year 2020 will reach a projected size of US$7.1 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6.4 Billion by the year 2027.We bring years of research experience to this 8th edition of our report. The 146-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed. Competitors identified in this market include, among others, AstraZeneca PLC; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche AG; Fortress Biotech, Inc.; Immutep Ltd.; Merck & Co., Inc.; Merck KGaA; Novartis International AG; Pfizer, Inc. |
INSIDER ACCESS PRIVILEGES
Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.
EXPERT PANEL REGISTRY
We're excited to add you to our Domain Expert Panel! Let's get you started.
*PRIVACY POLICY
YOUR PRIVACY MATTERS TO US!
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.